Summit Therapeutics Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -173.14 M

Summit Therapeutics Inc. Operating Cash Flow is USD -173.14 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 84.66% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Summit Therapeutics Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -93.76 M, a 162.55% change year over year.
  • Summit Therapeutics Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -35.71 M, a -49.64% change year over year.
  • Summit Therapeutics Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -70.92 M, a 17.24% change year over year.
  • Summit Therapeutics Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -60.49 M.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities